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A novel hotspot and rare somatic mutation
p.A138V, at TP53 is associated with poor
survival of pancreatic ductal and
periampullary adenocarcinoma patients
Gourab Saha1†, Richa Singh1†, Argha Mandal2†, Subrata Das3†, Esita Chattopadhyay1, Prasun Panja1, Paromita Roy4,
Navonil DeSarkar5, Sumit Gulati6, Supriyo Ghatak6, Shibajyoti Ghosh7, Sudeep Banerjee4, Bidyut Roy1,
Saurabh Ghosh1, Dipankar Chaudhuri2, Neeraj Arora4, Nidhan K. Biswas3 and Nilabja Sikdar1*

Abstract
Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a cancer of the exocrine pancreas and 5-year survival
rates remain constant at 7%. Along with PDAC, Periampullary Adenocarcinoma (PAC) accounts for 0.5–2% of all
gastrointestinal malignancies. Genomic observations were well concluded for PDAC and PACs in western countries
but no reports are available from India till now.
Methods: Targeted Next Generation Sequencing were performed in 8 (5 PDAC and 3 PAC) tumour normal pairs, using
a panel of 412 cancer related genes. Primary findings were replicated in 85 tumour samples (31 PDAC and 54 PAC)
using the Sanger sequencing. Mutations were also validated by ASPCR, RFLP, and Ion Torrent sequencing. IHC along
with molecular dynamics and docking studies were performed for the p.A138V mutant of TP53. Key polymorphisms at
TP53 and its associated genes were genotyped by PCR-RFLP method and association with somatic mutations were
evaluated. All survival analysis was done using the Kaplan-Meier survival method which revealed that the survival rates
varied significantly depending on the somatic mutations the patients harboured.
Results: Among the total 114 detected somatic mutations, TP53 was the most frequently mutated (41%) gene,
followed by KRAS, SMAD4, CTNNB1, and ERBB3. We identified a novel hotspot TP53 mutation (p.A138V, in 17% of all
patients). Low frequency of KRAS mutation (33%) was detected in these samples compared to patients from Western
counties. Molecular Dynamics (MD) simulation and DNA-protein docking analysis predicted p.A138V to have oncogenic
characteristics. Patients with p.A138V mutation showed poorer overall survival (p = 0.01). So, our finding highlights
elevated prevalence of the p53p.A138V somatic mutation in PDAC and pancreatobiliary PAC patients.
Conclusion: Detection of p.A138V somatic variant in TP53 might serve as a prognostic marker to classify patients. It
might also have a role in determining treatment regimes. In addition, low frequency of KRAS hotspot mutation mostly
in Indian PDAC patient cohort indicates presence of other early drivers in malignant transformation.
Keywords: Pancreatic ductal adenocarcinoma, Periampullary adenocarcinoma, Novel somatic hotspot mutation,
Frequently mutated genes, Next generation sequencing
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Introduction
Periampullary adenocarcinoma and PDAC account for
3.1% of all cancers and 4th leading cancer related deaths
in Western countries (Waddell et al. 2015). They belong
to a rare group of tumours which are often presented at
an advanced stage and have poor prognosis. PDAC is
tumour of pancreas which accounts for > 85% of all pancreatic head tumours (McGuire 2016). As the 5-year survival rate is constant at ~ 7%, it has been estimated that
PDAC will become 2nd most common cause of cancerrelated deaths by 2030 (https://seer.cancer.gov/) (Ying
et al. 2016). The incidence of PDAC in India is 0.5–2.4
per 100,000 men and 0.2–1.8 per 100,000 women (Thapa
2015). Only one study from Eastern India (Kolkata cancer
registry) showed 1.5% relative frequency in males and
1.2% in females for incidence of pancreatic cancer (Sen
et al. 2002). Histologically, PACs are of two types; intestinal and pancreatobiliary subtypes (Chandrasegaram et al.
2016; Kumari et al. 2013). The morphology of pancreatobiliary tumours show close resemblance to pancreatic tumours. The incidence of PAC is low, approximately 0.5–
2% of all gastrointestinal malignancies and 20% of all tumours of the extrahepatic biliary trees (Uomo 2014). Incidence of different subtypes of PAC varies among
geographical locations (Chandrasegaram et al. 2016).
Extensive studies in Caucasian population showed
KRAS, TP53, CDKN2A, and SMAD4 genes as the early
driver genes for PDAC (Hezel et al. 2006; Moore et al.
2003; Cowan and Maitra 2014). Using Next Generation
Sequencing (NGS) studies, other driver genes and core
signalling pathways have been identified for PDAC
(Waddell et al. 2015; Bailey et al. 2016; Biankin et al.
2012; Witkiewicz et al. 2015). There are few studies for
PACs which suggests a few other driver genes that were
not reported in PDAC (Gingras et al. 2016; Sandhu et al.
2016). Though the management and treatment are similar for PDAC and PAC, compared to the 7% of 5 year
survival of PDAC, PAC have better prognosis with 5 year
survival in more than 30% (Chandrasegaram et al. 2016).
PACs originating from the intestinal subtype have higher
survival than pancreatobiliary subtype. Most of the studies proposed that cigarette smoking and alcohol consumption are the most important contributing lifestyle
risk factors for PDAC in western world (Duell 2012). Although genomic landscapes of PDAC have been studied
extensively in “western” patient populations, the genetic
and epidemiological studies are limited in India. Appreciating the low incidence rate in India, compared to
most part of the world, we hypothesised that the mutation profile of pancreatic cancer from western populations may differ from the Indian patients. In the present
study, we performed NGS based DNA sequence analysis
of selected cancer drivers and other related genes in a
discovery cohort and re-sequenced a few functionally
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important regions by Sanger sequencing in a larger set
of validation cohort to understand the recurrent mutation status of these genomic loci in PDAC and PAC patients from India.

Methods
Sample collection and selection

The study was approved by the Institutional Review
Board (IRB) of Indian Statistical Institute, Kolkata and
all involved hospitals. It was carried out following approved guidelines and informed consent of patients. The
patient samples were collected from Tata Medical Center (TMC), Calcutta Medical Research Institute (CMRI),
and Medical College and Hospital, Kolkata, India in between September 2013 to July 2017. All samples were
confirmed by histopathologists of respective hospitals.
Tumour tissue samples containing > 70% tumour content were selected for the study. A total of 93 patients
comprising 36 PDAC, 28 PAC mixed subtype, 17 PAC
intestinal subtype, and 12 PAC pancreatobiliary subtype
were recruited in the study (S-Fig. 1). Eight patients (5
PDAC, and 3 PAC) were selected for NGS study and
remaining 85 patients (31 PDAC, and 54 PAC) were selected for validation using Sanger sequencing method.
Primary tumour, adjacent normal and blood samples
were collected from each patient. Another set of 24
PDAC samples were used for validation of KRAS 12th
codon mutation frequency.
DNA extraction

DNA was extracted from tissue and blood samples using
QIAGEN DNA extraction kit (DNeasy Blood and Tissue
Kit, QIAGEN Inc., Germany).
Library preparation and targeted next generation
sequencing

Sequencing libraries were prepared from 1 μg of genomic DNA. DNA was fragmented using a Covaris LE220
Focused-ultra sonicator using factory settings for an
average size of ~ 250 bp Sequence libraries were prepared using KAPA hyper-prep kit (KapaBiosystems, Wilmington, MA,USA) following end repair and A-tailing in
a single-tube protocol. Indexed KAPA Hyper libraries
were hybrid captured to NimbleGenSeqCap EZ custom
probes (Roche) according to the manufacturer’s protocol. Custom oligonucleotide probes (Agilent’s) were designed to enrich targeted regions of interest, spanning
412 cancer genes (mostly exons) associated with different cancer types. Library size distributions were checked
using Agilent Bioanalyzer and pooled library quantity
was estimated using QubitFluorometer and Trinean
DropSense96 spectrophotometer. Library DNA fragments immobilization and cluster amplification was performed on Illumina v4 flow cell using an IlluminacBot.
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Sequencing was performed using an IlluminaHiSeq 2500 in
high-output 100-bp paired-end mode using v4 reagents
(PE100). Sequence image data was analyzed using Illumina’s
Real Time Analysis v1.18.66.3 software, followed by demultiplexing of indexed reads and generation of FASTQ files,
using CASAVA1.8 pipeline (https://support.illumina.com).
Data analysis and somatic variant calling

Raw sequence reads were mapped to human reference genome build (hg19) using BWA-mem. A total 10,98,38,875
reads were aligned from 8 pair samples with an average of
68,64,929 reads per library. The average attained depth of
coverage for tumour samples were 137X and normal (blood)
samples were 67x. Duplicate removal was performed using
Picard (https://broadinstitute.github.io/picard/). Mapping
quality was restricted to 40, and only uniquely mapped reads
were kept. BAM files were generated using Samtools. GATK
(https://software.broadinstitute.org/gatk/) was used to do
local indel realignment and base quality recalibration. Somatic mutation calling was performed using four different orthogonal algorithms (frequency based, and heuristic
threshold based), Varscan2 (Koboldt et al. 2012), MuTect
(Cibulskis et al. 2013), STRELKA (Saunders et al. 2012) and
BbB (India Project Team of the International Cancer Genome Consortium 2013) by analyzing variant containing
reads from matched tumour and blood DNA data for every
patient. Only those variants were considered that passed
through filters of strand bias, total depth > 20, and population MAF < 0.01. Additional stringency of minimum 4 variant alleles at a variant site used to detect true somatic
alteration. Variants were annotated using ANNOVAR
(Wang et al. 2010). All variants were further manually curated using Integrative Genomics Viewer Version 2.3 (Broad
Institute, Cambridge, MA).
Analysis of Germline pathogenic mutation

DNA sequence reads generated from the blood tissues of
8 patients were also used to identify germline pathogenic
variants. All variants were called using the Unifiedgenotyper tool in GATK packages. All variants with QV > 30 and
depth of coverage greater than 10 were considered for further analysis. We have only focused on those mutations
which are relatively rare in population databases like 1000
genomes or ExAC. We chose 0.1% population frequency
cut-off to screen potential pathogenic variant candidates.
We adopted ACMG recommended scoring as well as
ClinVar annotation to annotate pathogenic or likely
pathogenic variants in this small case series.
Selection of region of interest and validation in a
different patient cohort by sanger sequencing method

From the identified variants of NGS study, regions of
interest were selected based on recurrent mutations,
hotspot mutated regions and frequently mutated genes.
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These exons were then amplified by polymerase chain reaction (PCR) using specific primers (S-Tab. 2) and sequenced
by Sanger DNA sequencing (ABI 3100 genetic analyzer)
method in another 85 tumour samples comprising 31
PDAC and 54 PAC. The selected regions from NGS study
were TP53_exon 5–8; NM:001126113, SMAD4_exon
6 & 9; NM:005359, ERBB2_exon 18 & 21; NM:004448,
ERBB3_exon 9; NM:001982, CTNNB1_exon 3; NM:
001904, KRAS_exon 2 and exon 3; NM:033360, PIK3R1_
exon 2; NM:181523, ITGB3_exon 10; NM:000212, BRAF_
exon 15; NM:004333, and EPHA2_exon 15; NM_004431.
These somatic mutations were further confirmed for their
absence in the corresponding blood or normal tissue
samples.
Mutation annotation and damaging property prediction
analysis

The mutational damaging property of non-silent mutations were predicted (in silico) by PROVEAN (Choi and
Chan 2015), SIFT (Sim et al. 2012) and Mutation assessor (Reva et al. 2011) tools (based on sequence homology and physical properties of amino acids). Public
databases like The Cancer Genome Atlas (TCGA), Catalogue of Somatic Mutation in Cancer (COSMIC) (Forbes
et al. 2017), ClinVar annotations were used to identify
reported and novel variants.
Verification and validation of somatic mutation by allele
specific PCR

Mutations at KRAS and TP53 (p.A138V), identified by
Sanger sequencing and NGS methods were further validated and reconfirmed in corresponding samples by allele
specific PCR (ASPCR) (Huang et al. 2015). Allele specific
primers were designed against mutant sequence and PCR
were performed to amplify DNA strands in the corresponding samples and visualized in 1% agarose gel. The
primers (S-Tab. 2) were designed so that the last base of
the forward primer changed as complementary to mutated
allele. The mutations analyzed by this method were KRAS:
p.G12A, KRAS:p.G12V, KRAS:p.G12D, KRAS:p.G12R, and
KRAS:p.Q61H. PCR were performed in 10ul reaction volume composed of 2.0 mM MgCl2 and 0.25 U Taq Polymerase. A generalized initial denaturation for 5 min in
95 °C was followed by 35 cycles of denaturation for 15 s at
95 °C. Primer specific annealing temperatures were as follows: annealing for 25 s at 59 °C for KRAS:p.G12A, 58 °C
for KRAS:p.G12R, 62.4 °C for KRAS:p.G12V, 61.9 °C for
KRAS:p.G12D, 58 °C for KRAS:p.Q61H and 61.7 °C for
TP53:p.A138V. We adopted a general PCR extension cycle
time and temperature which was 40 s at 72 °C. End of 35
cycles were always followed by an extension allowance
time of 5 mins at 72 °C. For KRAS G12 codon mutations,
KRAS_G12_R reverse primer was used, for KRAS Q61
codon mutation KRAS_Q61_R reverse primer was used.
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For TP53 A138 codon mutation, TP53:p.A138V mutant
forward and mutant reverse primers were used with corresponding TP53_A138_R reverse, TP53_A138_F primers
were used respectively. All primers used in this study are
listed in S-Tab. 2.
KRAS 12th codon mutation detection by two-step
enriched-semi nested PCR

The presence of mutation in codon 12 of KRAS was detected using a Two-Step Enriched- Semi Nested PCR
(Slebos et al. 2000). This technique involves two PCR
amplifications, each followed by a restriction digestion.
Using mismatch primer A (precise nucleotide change),
and primer D a 197 bp fragment containing artificially
generated restriction enzyme site (for BstN1) at the
12thcodon of K-ras gene was amplified in the first PCR.
After digestion with BstN1, the PCR products encoding
mutant and normal sequences could be distinguished as
197 bp, 160 bp and 37 bp, band sizes respectively, in 2%
agarose gel. A second PCR was done again using mismatched primer A and primer B (precise nucleotide
change) to yield a 164 bp product using of the digestion
resistant DNA fragment and undigested first PCR product (which was unenriched of mutant sequences). This
time, PCR products with mutant and normal sequences
could be distinguished as 147, 17 bp and 111, 36, 17 bp
band sizes, respectively, after second BstN1 digestion
using unenriched mutant sequences from first PCR
product. The mutant sequences reconfirmed with DNA
fragments 147, 36 bp band sizes by second digestion
with BstN1 from enriched mutant sequences.
KRAS mutation validation by ion torrent sequencing
method

Six samples comprising 3 KRAS mutant and 3 KRAS
wild type were selected for sequencing by Ion torrent
PGM platform. DNA was extracted using QiagenGeneRead™ DNA FFPE kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. The NGS assay was
performed with 10 ng of input DNA using the Ion
Ampliseq Cancer Hotspot panel v2 [CHPv2] (Ampliseq,
Life Technologies) on the Ion torrent PGM platform.
The Ion AmpliSeq Cancer Hotspot Panel v2 is designed
to amplify 207 amplicons covering approximately 2800
COSMIC mutations from 50 oncogenes and tumour
suppressor genes. The amplicons were then digested,
barcoded and amplified using the Ion Ampliseq Library
kit 2.0 and Ion Xpress barcode adapter’s kit (Life technologies) according to the manufacturer’s instructions.
The library was prepared using the Ion Ampliseq Library
kit 2.0 with some modifications (Cycling was performed
for 22 cycles for FFPE in a Veriti Thermal cycler and the
reaction was reduced to half). The library was then
quantified using the Ion Taqman quantitation kit (Life
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technologies). All the libraries were pooled in equimolar
concentrations (100pM). The emulsion PCR was performed using the High Q view OT2 kit (Life technologies). The template ISP were enriched, loaded on a 318
chip and sequenced on a PGM sequencer with the Ion
PGM High Q view sequencing 200 kit v2 according to
the manufacturer’s instructions. Here we emphasized
only on KRAS gene to validate mutations identified by
other methods.
Data analysis for the ion torrent sequencing data

The sequencing reads were aligned to hg19 using Torrent Suite 3.4.2. The sequences were analysed using variant calling software (Ion Reporter Annotate variants
version 5.4, 5.6 and 5.10) caller to identify variants relevant to the clinical indication. The raw data was analysed using the Ion Browser Torrent Suite platform 5.05,
5.6 and 5.10 (Life technologies). Cases for which the
number of mapped reads was < 100,000 and the average
base coverage was <100X was rejected and repeated
from library amplification. Mutations reported in the
COSMIC (Sanger Institute Catalogue of Somatic Mutations in Cancer) database (http://www.sanger.ac.uk/cosmic) were reported whereas silent or intronic mutations
were excluded. We have already established 2% as the
limit of detection for this panel.
Molecular dynamics simulation using Desmond

Molecular dynamics (MDS) simulations of wild type and
p.A138V mutant at p53 were performed. Desmond version
5.6 was used for the molecular dynamics simulation study.
Pre-processing of PDB file

The wild type complex structure for molecular dynamics
simulation has been adapted from the crystal structure
of p53 core domain in complex with DNA (PDB code:
4HJE). The mutated structure (p.A138V) of the complex
was generated using Maestro 11.8.012. The monomers
of (i) wild type and (ii) mutant TP53 DNA binding domain bound to DNA were prepared using the Protein
preparation wizard for molecular dynamics simulation.
In addition, twin operations of H-bond assignment at
pH 7.0 and energy minimization to eliminate any unfavourable interaction between protein and solvent molecules restrained energy minimization of heavy atoms at
a minimum 0.30 Å RMSD range were also done for both
systems using the Protein preparation wizard.
Solvent system addition to pre-processed molecular
complexes

Desmond System Builder (https://www.schrodinger.com/
desmond) was used to solvate both molecular complexes
explicitly with TIP3P solvent system in an orthorhombic
water box. The boundaries of each solvent box were at an
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average of 10 Å distance from the protein complex in
three dimensions.

for the effect of solvent on docking and de-solvation energy of the protein-DNA complex were done.

Molecular dynamics simulation and analysis

Tissue microarraySpot study for p53 in tumour tissues

Both solvated complexes were subjected to 300 ns molecular dynamics simulation with a 10 ps trajectoryrecording interval using Desmond 5.6 (https://www.
schrodinger.com/desmond) at constant temperature
(300 K) and constant pressure (1.01325 bar). The model
systems were relaxed before simulation. The force field
that was used was OPLS-2005 (Optimized Parameters
for liquid simulations force field-2005 version) (Banks
et al. 2005). This force field calculates the collision diameter for mixed interactions as the geometric mean of the
values for the two component atoms.
The simulation outputs were then used to analyse time
dependent average RMSD and secondary structure elements (SSE) of the protein complexes. The average residual RMSF of Wild Type and mutant p53 was also
analysed from the simulation data. All these analyses
were done using the Simulation interaction diagram
panel of Desmond. Using Desmond Molecular dynamics
event analysis panel, intermolecular hydrogen bonding
formation between protein and DNA during the entire
simulation has been calculated. The averaged value of
total potential energy of the protein (p53 DNA binding
domain/DBD comprises 91–291 aa.) part was calculated
using the Desmond Molecular dynamics event analysis
panel from the p53 DBD-DNA complex structures of
entire dynamics simulation. Desmond trajectory clustering was used to cluster the structural frames according
to their RMSD. Backbone and side chain RMSD were
used to prepare the RMSD matrix at frequency of 5.

The tumour site, morphologic subtype, grade, tumour
size, margin status, presence of lympho-vascular (LVI)
and perineural invasion (PNI), lymph node ratio (LNR),
extranodal extension and stage were assessed. The tumours were staged according to the criteria in the
American Joint Committee on Cancer (AJCC) 7th edition. A tissue microarray (TMA) block was made with
30 cases (TP53 mutant) using 3mm diameter cores. Immunohistochemistry with DO-7 clone of p53 antibody
(mouse monoclonal, sc-47698) from Santa Cruz, CA,
USA was performed on the BondMAX automated immunohistochemistry staining platform from Leica using
the standard operating protocols. The tissue cores were
then scored for p53 immunostaining. We recorded the
percentage of cells which stained positively as well as the
intensity of staining. The cases in which more than 70%
of the tumour cells stained positive with either moderate
or strong intensity (positive) or those with absent staining (null-pattern), were considered positive. Other staining patterns were termed equivocal, representing wild
type staining (Kobel et al. 2016).

p53-DNA binding interaction analysis using Haddock

Docking experiments were performed using (i) wild type
and (ii) p.A138V mutant p53 DNA binding domain
monomer against DNA as target. The wild type monomer was prepared from the crystal structure of the complex [PDB Code: 4HJE] available in protein data bank
using UCSF chimera (Pettersen et al. 2004). The mutant
monomer was modelled through the Swiss Model web
server using the wild type TP53 (chain A of PDB code:
4HJE) as template. The DNA was prepared using 3D –
DART web server (van Dijk and Bonvin 2009) for the
docking purpose [coordinates of DNA are adopted from
PDB code: 4HJE]. Haddock 2.2 web server Guru Interface (van Zundert et al. 2016) was used for macromolecular docking. Different docking parameters were
utilized other than that of the default setting for
optimization of the p53-DNA interaction and subsequent analysis. All hydrogen atoms were used for calculation of distance restraints and additional calculations

ERBB2/Her2-Neu amplification detection by TaqMan DNA
copy number assay

ERBB2 amplification was assessed by real time PCR using
TaqMan probe comparing tumour vs. normal tissue/blood
DNA samples (Vincent-Chong et al. 2017). Copy number
analysis for ERBB2 was done on all 93 samples using TaqMan Copy Number Assay (Hs00817646_cn) (Applied Biosystems, CA, USA). For copy number variation,
2-Δctvalues of tumour and normal group were compared by
Wilcoxon signed rank test to identify significant difference
of fold change in ERBB2 copy numbers in tumour and normal groups (R Packages, R Studio, ggPlot2). Relative quantification determined as 2-ΔΔct was calculated for each of the
samples to identify copy number change. Above 2 fold
change was considered as copy number changes. (Detailed
method is in supplemental section).
Genotyping of key polymorphisms of TP53 and its
associated genes and analysis

In order to analyse association between TP53 somatic
mutations and germline polymorphisms, we genotyped
key polymorphisms in TP53 (Arg72Pro-rs1042522, PIN3
Ins16bp, Intron 6 MspI-rs1625895), MDM2 (SNP 309rs2279744), p21 (Codon 31-rs1801270), and p73 (73 bp
Del) by PCR-RFLP and/or PCR method. We choose logistic regression and multifactor dimensionality reduction (MDR) model to study polymorphisms interactions
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with somatic mutations in our patient samples. (Detailed
method in supplemental section).
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Table 1 Characteristics of Demography and Clinicopathological
parameters of total patients
Total Patients Recruited in the Study

Statistical analysis
Survival analysis

Overall Survival (OS) analysis was done by KaplanMeier estimator using SPSS Inc. (Version 16.0, Harvard
University, MA, USA). OS was calculated from the date
of pathologic diagnosis to the date of death or the date
of the last confirmed contact. Survival curves were generated using the Kaplan-Meier method and assessed for
statistically significant differences (p < 0.05) via the log
rank test. We compared OS difference between patients
having p.A138V mutation in TP53 with patients who do
not harbour this mutation and also with patients who do
not harbour any TP53 mutations. Overall survival were
also compared between PDAC and PAC patients group,
and separately between ERBB2/Her2-neu amplified and
ERBB2/Her2-neu non amplified group to study effect of
ERBB2/Her2-neu amplification in patient survival. In
addition to that, to identify effect of SNPs in patient survival, we estimated OS difference between risk genotypes
and non risk genotypes of the stated polymorphisms at
TP53 and other TP53 associated genes. Here, we choose
a three dimensional survival model for all the polymorphisms where we compared at least two loci containing
the risk genotypes out of three loci vs. at least two loci
containing the non risk genotypes out of three loci. The
risk vs. non risk genotypes were assumed in dominant
model.
Simulation analysis for targeted exome sequencing

To address the low sample size issue in our cohort, we
designed a simulation study with patient datasets from
the TCGA Pancreatic Ductal Adenocarcinoma – PDAC
and Ampullary Carcinoma-AC project (Yachida et al.
2016; Cancer Genome Atlas Research Network 2017). In
the simulation study, we randomly sampled data from 8
patients from the 150 TCGA-PDAC patients and
60 AC patients separately and quantified occurrences of
non-silent somatic mutations in TCGA reported PDAC
driver genes and AC driver genes from downloaded
somatic variant data. This random selection based sampling study was iterated for 10,000 times to obtain the
mutation frequency estimates.

Results
Patient characteristics

The mean age of the patients was 53±10.36. Twelve percent
(n = 11) of the patients had pancreatitis history (Table 1,
and S-Tab. 3). The frequencies of pancreatitis were almost
similar between PDAC and PAC patients (45% vs. 55% respectively). According to 7th edition of American Joint
Committee on Cancer (AJCC) nomenclature on the stages

n = 93

Demography & Clinicopathological Characteristics
Age (Mean)

53 ± 10.36

Smoking Habbit

34% (n = 32)

Alcohol Habbit

18% (n = 17)

Pancreatitis

12% (n = 11)

Tumour Types
PDAC

39% (n = 36)

PAC unknown subtype

30% (n = 28)

PAC Intestinal subtype

18% (n = 17)

PAC Pancreatobiliary subtype

13% (n = 12)

Tumour Classification (7th AJCC)
Stage IA

6% (n = 6)

Stage IB

20% (n = 19)

Stage IIA

14% (n = 13)

Stage IIB

54% (n = 50)

Stage III

4% (n = 4)

Stage IV

1% (n = 1)

Tumour Differentiation
Well differentiated

35% (n = 33)

Moderately differentiated

41% (n = 38)

Poorly differentiated

13% (n = 12)

Unidentified

11% (n = 10)

Lymph Node
Present

58% (n = 54)

Absent

42% (n = 39)

(pathological) of the tumours were; IA 6% (n = 6), IB 20%
(n = 19), IIA 14% (n = 13), IIB 54% (n = 50), III 4% (n = 4),
and IV 1% (n = 1). Thirty five percent (n = 33) of the tumours were well differentiated adenocarcinoma (WDA),
41% (n = 38) were moderately differentiated adenocarcinoma (MDA), 13% (n = 12) were poorly differentiated adenocarcinoma (PDA), but grades were not available in the
remaining patients (Table 1, and S-Tab. 3).
Landscape of somatic mutation in discovery cohort

Using NGS method, we have identified total 48 somatic
mutations from 8 patients in exons from 412 genes (Fig. 1).
Seventy three percent (n = 35) of the variants were identified by at least two variant callers (S-Tab. 4). These 48 somatic mutations comprise 65% (n = 31) missense, 10% (n = 5)
synonymous, 10% (n = 5) UTR, 8% (n = 4) nonsense, 4%
(n = 2) InDel, and 2% (n = 1) splice site mutations. Genes
which were mutated in 2 or > 2 samples are following:
KMT2C (n = 5), TP53 (n = 3), SMAD4 (n = 2), CTNNB1
(n = 2), ERBB2 (n = 2), NOTCH1 (n = 2), PARP1 (n = 2),
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Fig. 1 Somatic mutations identified by different variant caller. Somatic mutations identified by 4 different variant callers Varscan, Strelka, Mutect
and BbB from 8 tumours. Black coloured boxes indicate mutation identified by variant caller and white boxes indicate “no mutation” identified by
that variant caller. Mutations marked with “*” were selected for validation cohort. Mutations marked with “†” observed twice in patients

PIK3R1 (n = 2), and PIK3CD (n = 2) genes (Fig. 1). All the 3
mutations in TP53 in 3 samples were identified in DNA
binding domain. The mutation p.S45F in CTNNB1 and
p.S491A in PIK3CD was recurrent as observed in two different patients. Only one mutation, p.G12R was observed in
KRAS in 1 patient only. Somatic mutations, identified by
NGS, were also identified by Sanger sequencing method
which showed clear peak for the mutant allele (S-Fig. 2).
Our additional simulation analysis with published datasets
(see methods) showed that somatic mutations in all known
PDAC driver genes (KRAS, TP53, SMAD4, CDKN2A, GNAS,
RNF43, ARID1A, TGFBR2, RREB1, and PBRM1) and AC
driver genes (KRAS, TP53, APC, ELF3, SMAD4, CTNNB1,
and MUC4) can be reliably detected even in small subset of
8 patients when randomly selected (10,000 iterations) from
large patient cohorts’ datasets (S-Tab. 5).
Characteristics of Germline mutations

We performed the germline mutation analysis on NGS sequenced PAC and PDAC patients only. To highlight, we
identified 2 of these 8 patients harbouring DNA repair
pathway associated germline pathogenic/likely pathogenic
mutations in BRCA1:NM_007297.3:c.4042C > T:p.Q1348*
and in ETS2:NM_001256295.1:c.191G > A:p.W64*. We
have also detected a common variant in FGFR4 (NM_
213647.2:c.1162G > A:p.G388R) in 5 of the 8 patients,
which is associated with cancer metastatic progression
(Ezzat et al. 2013). In summation, we did not detect any
second hit to these genes in the respective tumour samples.
Landscape of somatic mutation in validation cohort

Sanger sequencing method identified 66 somatic mutations in 16 exons of 10 genes in the validation cohort (STab. 6). Out of these 66 alterations, 58 were missense, 5
were silent, and 3 were stop-gain mutations, respectively.
PCR amplification for KRAS exon2 could not performed
in 10 patients (6 PDAC and 4 PAC) due to bad sequence
quality of the PCR products in this region. Thus KRAS
mutation frequency was calculated for 75 case series. In

the validation study, 41% mutations were observed in selected exons of TP53, 21% mutations in KRAS, 7% mutations in SMAD4, 5% mutations in CTNNB1, 4%
mutations in ERBB3, 1% mutation in EPHA2, and 1%
mutation in ERBB2/Her2-neu gene. But, no mutations
were identified in the exons of BRAF, PIK3R1, and
ITGB3 genes.
Spectrum of somatic mutations in entire patient cohort

A total 114 somatic mutations comprising 112 point
mutations and 2 deletions were identified in the total of
93 patient samples. Out of these 112 point mutations, 92
were missense, 7 were silent, 7 were nonsense, 5 were at
UTR, and 1 was splice site alteration. The transition/
transversion ratio was 2 with 67% transition and 33%
transversion (S-Fig. 3). Among the mutations, 56% were
identified in PAC patients (n = 64) whereas 44% mutations identified in PDAC patients (n = 50). TP53 was
identified as the most frequently (41%) mutated gene in
our patient cohort (Fig. 2). Other recurrently mutated
genes identified in our patient population were KRAS
(21%), SMAD4 (7%), CTNNB1 (7%), and ERBB3 (4%)
(Fig. 2, S-Fig. 4). Whereas, less number of mutations
were observed in the selected regions of ERBB2 (3%),
EPHA2 (2%), PIK3R1 (2%), ITGB3 (1%), and BRAF (1%)
genes in our patient population (Fig. 2). Recurrent alterations in these genes were p.G12D (n = 8), p.G12A (n =
3), p.G12V (n = 2), and p.Q61H (n = 2) in KRAS, p.S45F/
P (n = 5) in CTNNB1, and p.R361H/S (n = 2) in SMAD4
(S-Fig. 4). In our study, a total of 58 different types of
missense mutations were identified. Seventy five percent
(n = 44) of them were identified as probable damaging
mutations by at least one prediction tools (Provean,
SIFT, and Mutationassessor). In addition, 19 of the variants were annotated as pathogenic or likely pathogenic
and 3 variants were reported as variants of uncertain significance in ClinVar database (S-Fig. 5). Sixty seven percent (n = 68) of the identified variants are also reported
in COSMIC database. Whereas, 50% (n = 51) of the
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Fig. 2 Patient characteristics and observed mutations in selected genes in total patient cohort(n = 93). Patient characteristics and observed
mutations in selected genes in total patient cohorts (n = 93). Patient’s indicated with sky coloured boxes were the samples studied in targeted
exome sequencing (NGS) method and remainingsamples were studied by Sanger sequencing method. The colours of the boxes in the
demography and clinicopathological characteristics were explained in the small figure below the main figure. The blue boxes in the gene’s rows
indicated presence of missense mutation, pink coloured boxes indicated presence of nonsense mutation, magenta coloured boxes indicated
presence of silent mutation and yellow coloured boxes indicated presence of both missense and silent mutation in that gene for corresponding
patient. In the ERBB2 row, dark purple coloured boxed indicate > 2 fold ERBB2/HER2 amplification detected in the corresponding patient

variants were reported in TCGA database. However,
when we compared mutations identified in our PDAC
patients (n = 36) with those in TCGA PDAC cohort (n =
185) only 13% (n = 6) of the mutations were found to be
common (S-Fig. 6).
Low frequency of KRAS mutations detected in PDAC and
PAC cases

KRAS is known to be very commonly mutated driver gene
(90%) in pancreatic cancer (Cancer Genome Atlas Research Network 2017; Maitra and Hruban 2008). But, in
this study, we found relatively lower frequency (i.e. 33%)
of KRAS mutation in PDAC tumours. To revalidate this
lower frequency, we adopted three independent mutation
validation approaches. The mutations in KRAS and
p.A138V mutant of TP53 (mTP53) were further verified
by allele specific PCR (ASPCR) (S-Fig. 7). Apart from
Sanger sequencing method, KRAS 12th codon mutations
were additionally validated by Two-Step Enriched-Nested
PCR (S-Fig. 8). In case of PDAC, a total 10 alterations (8
in codon 12 and 2 in codon 61) were observed in 30 studied patient tumours. Whereas, a total of 7 alterations were
identified in 53 PAC patient tumours (Table 2). In PDAC

KRAS mutation study, 8 were identified by Sanger sequencing, 9 were validated by ASPCR and all 8 mutations at
codon12 of KRAS were again validated by RFLP method
(S-Fig. 9). In addition, 33% (8 out of 24) KRAS 12th codon
mutations were identified in another independent cohort
of 24 PDAC patients and validated by RFLP method. As
we have observed KRAS has lower mutation frequency
among Indian patient population compared to patient
population from Western countries, we have also validated mutation frequencies by Ion Torrent method in 6
samples (3 KRAS mutants and 3 KRAS wildtype) to check
the concordance with our Sanger sequencing method,
ASPCR and RFLP results. All 3 KRAS mutants (G12D,
G12C and Q61H), identified previously by other method,
were also validated by Ion Torrent sequencing method.
Novel hotspot somatic mutation at TP53 is associated
with poor prognosis

A total of 38 somatic alterations were identified in TP53
DNA Binding Domain in all samples. Frequencies of
these mutations among PAC and PDAC patients i.e. 25
in 57 PAC and 13 in 36 PDAC tumours, were not significantly different by Fisher exact test (p = 0.51). Thirty

(2020) 26:59

Saha et al. Molecular Medicine

Page 9 of 21

Table 2 Identification of KRAS mutation in patient cohorts using different methods
Cohort

Total KRAS Mutation Identified
(Codon 12 & 61)

Method

Tumour Type

KRAS Mutation
Frequency

Discovery Cohort (n = 8)

N =1

NGS

PDAC (n = 5)

0%

PAC (n = 3)

33% (n = 1)

Validation Cohort (n = 85)/ N = 16
(n = 75)a

Sanger
Sequencing

PDAC (n = 25) 32%(n = 8)

PCR-RFLP of 12th
Codon

PDAC (n = 25) 32%(n = 8)

ASPCR

PDAC (n = 25) 36%(n = 9)

PAC (n = 50)

PAC (n = 50)

PAC (n = 50)
Independent Patient
Cohort (n = 24)

N =8

PCR-RFLP of 12th
Codon

Total KRAS mutation
Frequency
12%

19%

14% (n = 6)
19%

14% (n = 6)
20%

12% (n = 6)

PDAC (n = 24) 33% (n = 8)

33%

a

In case of validation cohort PCR amplification of KRAS exon 2 for 10 samples could not performed due to technical error

four of these 38 mutations were missense, 3 were nonsense, and 1 was silent mutation. Some of these TP53
mutations were recurrent across tumours. We detected
a novel hotspot missense mutation p.A138V, which was
detected in 17% (n = 16) of all patients (Fig. 3a, and SFig. 10). All these p.A138V mutations were revalidated
by ASPCR and also by Sanger re-sequencing of the
ASPCR amplicon product (S-Fig. 7f). Surprisingly, the
histological features of these 16 tumours resemble more
close to PDAC and pancreatobiliary subtype of PAC.
Briefly, 9 of 16 (56%) p.A138V mutations were in ductal
tumours in origin, 2 (12.5%) were in pancreatobiliary
subtype of PACs, 3 (19%) were in PACs mixed subtype
and remaining 2 (12.5%) were intestinal type in origin
(Fig. 3b). In TCGA database, this p.A138V mutation was
reported to be in very low frequency {i.e. 0.04%, 4 out of
10,202 across Genomic Data Commons (GDC) database}
but none of them were in pancreatic cancer. Analysis of
this mutation, by all 3 functional prediction tools, identified it as a damaging missense mutation. The KaplanMeier survival analysis showed patients (n = 16) with the
mutation at p.A138V in TP53 has significantly poorer
survival than patient (PAC and/or PDAC) having wild
type variant (p = 0.02) (Fig. 4a). We also observed that
patients with p.A138V mutation had a worse survival
rate than the remaining ones (PAC and PDAC) (p =
0.01) in our patient cohort (Fig. 4b). It is to be noted
that PDAC patients had a significantly poorer overall
survival than PAC patients (p = 0.002) (Fig. 4c). The
other detected recurrent TP53 mutations in DBD were
p.E285K (n = 2), p.G245S (n = 2), p.R175H (n = 2), and
p.V272M (n = 2) (Fig. 3a).
Molecular dynamics simulation analysis showed that
p.A138V mutant behaves as a novel cancer mutant in TP53

We computed a residue specific differential Root Mean
Square Fluctuation (RMSF) pattern in wild type and mutant p53 protein. At residue162–194 (L2 and helix H1

positions) we estimated more substantial fluctuations in
wild type protein compared to its mutant type counterpart. This changed lability (i.e. conformational flexibility)
may result in destabilization of the entire protein and
also loss of affinity in the protein-DNA interaction in
mutant. This was generally conferred from binding free
energy. The fragment L2 (residues 162–194) and H1
(residues 163–178) creates a Zn2+ ion binding pocket with
two residues 176C and 179H flanking it. The RMSF value
suggests that the wild type protein has greater flexibility in
that region of the protein as we observed the L2 and
H1and other regions showing higher RMSF values in the
wild type compared to the mutant.This illustrates that the
p.A138V mutation at p53 loses its flexible conformation
and becomes more rigid (Fig. 5a). This lower flexibility
may affect the binding of the mutant to DNA and thereby
reduce the tumour suppressor activity of the protein.
Hence, next we performed DNA and protein molecule
interaction by Haddock. The root mean square deviation
(RMSD) for backbone, side chain and heavy atoms were
analysed to study the convergence of the protein system
for both wild type and p.A138V TP53 mutant. In the
RMSD plot, the native and mutant p53 structure show a
similar pattern of deviation from the start till 80 ns. Following this, the mutant structure showed a decrease in RMSD
value in comparison to the native structure (upto 300 ns).
Subsequently, the mutant p.A138V structure showed a
smaller deviation till the end of simulations while the native structure indicated the same extent of deviation from
the start till 100 ns and again from 150 ns to the end of
the simulations (Fig. 5b).
In wild type, the SSE plot showed the presence of a
small helix H1 (very less probable), a marginally more
prominent existence of a small beta strand and a big
loop L2. The SSE for mutant indicated small helix H1
which had become more prominent and strand had fully
converted into a loop. During the simulation we noticed that the small helix H1 was predominant in the
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Fig. 3 Mutational spectrum of TP53 DNA binding domain. Mutational spectrum of TP53 DNA binding domain. a Frequency of TP53 DNA binding
domain mutations observed by cBioPortal. The red circle is the p.A138V mutation identified in 17% of all TP53 mutations. b Patients (n = 35) with
observed TP53 mutations (i.e. 38% of total samples). In the sample row, sky coloured columns are the samples studied in targeted exome
sequencing (NGS) and white columns are the samples studied in Sanger sequencing methods. The brown boxes in the TP53 p.A138V row
indicate presence of p.A138V mutations in the samples. The colours of the boxes in the demography and clinicopathological characteristics were
explained in the pictures below the main picture

mutant protein. The trajectory clustering analysis using
backbone and side chain RMSD resulted in 26 and 30
clusters for wild type and mutant TP53 respectively
(data not shown).
Total energy of p53 DBD was measured and statistically analysed during the simulation of the complexes. In
our simulation, the average values of total potential energy (of only p53 DBD) were estimated as 12,383.123±
75.461 and 12,470.351±97.519 kcal/mol respectively for
wild type and mutant p53 DBD (data not shown). This
result also supports the hypothesis that wild type DBD
has greater stability than the mutant for the entire

simulation period. The intermolecular hydrogen bonding
significantly characterizes binding energy change between wild type and mutant p53 DBD binding to DNA.
Two types of intermolecular hydrogen bonds (O-H and
N-H) are formed within the complexes in the 40 ns
simulation timespan. The overall intermolecular hydrogen bonding statistics predicted greater number of intermolecular hydrogen bonds in wild type complex than in
the mutant complex. During the simulation, number of
overall intermolecular hydrogen bonding interactions
varies with time in a range of 3–15 in wild type and 4–
13 in mutant with the average of 8 and 7 for wild type

Saha et al. Molecular Medicine

(2020) 26:59

Page 11 of 21

Fig. 4 Survival graph observed by Kaplan-Meier estimator using SPSS. Overall survival comparison between different patient groups. a KaplanMeier overall survival analysis of patients with TP53 p.A138V mutations and patients with “no TP53” mutations. b Kaplan-Meier survival analysis of
patients with TP53 p.A138V mutations and patients with “no TP53 p.A138V mutations”. c Kaplan-Meier overall survival analysis of PDAC and PAC
patients. Number of patients denoted by “n” in each of the survival curves

and mutant respectively (S-Fig. 12). This supports the
possibility of strong DBD-DNA binding in wild type
compared to the mutant. Furthermore, this possibility is
also supported by the count of N-H hydrogen bonds between DBD and DNA that are 9 and 5 for the mutant
and wild type, respectively, throughout the simulation.
However, within the wild type DBD-DNA dynamics,
R280 and N288 N-H bonds have 510 and 487 occurrence frequency respectively within 1000 frames. By
comparison in mutant type DBD-DNA dynamics, R248
is the only residue, which has an occurrence frequency
of 203; occurrence frequency of 8 other N-H bonds is
much less (data not shown). This observation also supports the conclusion that greater fluctuations of strong
hydrogen bonding (N-H), lead to greater flexibility and
instability of the mutant than that of the native protein.
Additionally intermolecular hydrogen bond analysis
from the trajectory visualization clearly highlighted a L2
loop which was highly active for mutant protein regarding intermolecular hydrogen bonding (residues Q165

and Q167) with DNA. In contrast, in wild type protein,
the L2 loop was not involved in intermolecular hydrogen
bonding with DNA. It is thereby feasible that the increased RMSF of the L2 loop might have been due to
the increased but less specific hydrogen bonding with
DNA, which was not present in the wild type protein. In
the wild type protein, the L1 loop was highly involved in
intermolecular hydrogen bonding with K120 being the
key residue forming hydrogen bond with DNA. However
in the mutant protein the interaction of L1 loop with
DNA had reduced, though K120 was still the most interactive residue forming hydrogen bond. Alikely explanation of these results would be that a reduced RMSF of
L1 loop in mutant protein was due to the reduced
hydrogen bonding of L1 loop with DNA. Therefore mutation from alanine (A) to valine (V) at 138th position
rendered L1 loop more rigid and L2 loop more flexible
in comparison to the wild type. Consequently, the binding conformation of the protein might have been altered
making the protein-DNA interaction more unstable.
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Fig. 5 Molecular dynamics analysis of wt-type TP53 and mTP53 (p.A138V). Comparison of RMSF and RMSD plot between wild type and mutant
(p.A138V) Tp53 protein. a The plot represents the time dependent RMSF plot of the TP53 DNA binding domain of wild type and p.A138V mutant
respectively. Residue 91–291of Tp53 protein represents the DNA binding domain/core domain of Tp53 crystal structure 4HJE.With respect to
residues mapped in Tp53 protein, different loops and helixes were denoted like L1 loop (residues 112–124), L2 loop (residues 164–194)
(interrupted by Helix H1 residues 163–178), and L3 loop (residues 239–251). b The plot represents the time dependent RMSD plot for backbone,
side chains and heavy atoms of the TP53 DNA binding domain of wild type (left) and TP53 p.A138V mutant (right)

Interaction between DNA and protein (wild type vs.
mutant p53) through molecular docking

Solvated Docking analysis with OPLS force field gave
Haddock scores for docking with corresponding desolvation energies calculated. Haddock scores are − 11,
660.5+/−4.7 and − 11,538.8+/−31.7 (kcal/mol) for wild
type p53 and mutant p53 protein respectively. Z-scores
for both types were − 1.9. Buried Surface Area (BSA) for
wild and mutant type are 1459.6+/−90.1 and 1230.9+/
−78.8 Å2 respectively. The less negative values of the
HADDOCK score of the p.A138V mutant p53 complexes (DNA and protein) suggested a lower affinity between biological partners (p53 protein-DNA) compared
to that in native complex (S-Tab. 7). The BSA for wild
type increased compared to mutant type indicating
greater stability in the former. Thus, protein-DNA

docking analysis and intermolecular hydrogen bonding
patterns confirm that p53 protein has significantly decreased interaction with DNA due to the p53 DBD mutation at p.A138V, which may in turn affect function of
p53 protein and inhibit tumour suppression.
p53 nuclear accumulation is highly associated with
presence of p53 missense mutation (p.A138V) in TMA of
tumours

The sensitivity and specificity of the p53 TMA assay
were examined in 2 pancreatic and periampullary tumours having p.A138V missense mutations, and 7 others
known TP53 missense DBD mutants included (p.R175H,
p.A161T, p.V216E, p.V272M, p.E285K (2) (McGuire
2016), and p. K132E,). For tumours, p53 immunostaining
was initially evaluated on TMA spots of IHC. We have

Saha et al. Molecular Medicine

(2020) 26:59

adopted 3 tier scoring system to describe p53 staining:
Overexpression (OE), Complete Absence (CA) or Wild
Type (WT) in our TMA spot study. For negative control
wild type and null type TP53 were taken for TMA analysis. The two cases of p.A138V mutant showed p53 nuclear accumulation/retention, and positive staining (>
70% of the tumour cells showing strong nuclear staining). For the p53 DBD mutations p.V272M, p.R175H,
p.E285K, p.K132E also showed p53 nuclear accumulation and positive staining. Previously, p.R175H was well
documented as a gain of function/oncogenic hotspot
mutation. Thus all mutations showed positive or overexpression (OE) and this is most commonly associated
with missense TP53 mutants. In the negative control, we
observed there is null type staining of p53 in the null
type/complete absence tumour. We also detected
equivocal p53 staining for wild type cases. In 5% of the
cases, we have observed discordance between p53 missense mutation, and nuclear accumulation of p53 in
TMA spot. It is noteworthy that in all of these cancers,
heterogeneity of TP53 expression could be observed,
raising the possibility of focal TP53 mutations in a
tumour subclone that may not have been detected by
the sequencing assays. High staining or positive staining
also can be observed in case of frameshift, nonsense mutations and splice variants (Fig. 6).
Association between combined genotypes of TP53 and
SNPs of its related genes with patient OS

We have typed selected polymorphisms at TP53 and its
related genes (p73, MDM2, and p21) for all 93 patient
samples. In combined genotype analysis we found in between TP53 codon 72, MDM2 SNP 309 and p73InDel
73 bp loci, patients carrying risk genotypes in these loci
(R/R, or R/P + G/G, or T/G + D/D, or I/D) had significantly poorer OS (p = 0.04) compared to those carrying
non risk genotypes in at least two loci (P/P + T/T + I/
I) + (R/R, or R/P + T/T + I/I) + (P/P + G/T, or G/G + I/
I) + (P/P+ T/T + D/D, or I/D) (Fig. 7a). In addition, we
also observed in these three loci, patients containing I/I
genotype of p73InDel 73 bp polymorphism with combination of risk genotype in the other two loci (TP53 codon
72: R/R, or R/P + MDM2 SNP 309: G/G, or T/G) also
had poorer OS (p = 0.04) compared with the same combination like above (Fig. 7b). Furthermore, it is important to note that we could not identify any association
between germline polymorphisms and TP53 somatic
mutations in DBD by both logistic regression and multifactor dimensionality reduction (MDR) model.
ERBB2/HER2-neu amplification status in tumours

ERBB2/Her2-neu amplification was identified in 30% (17
out of 57) of the PAC and 19% (7 out of 36) in PDAC
samples (Fig. 2, S-Fig. 13, and S-Tab. 8). Among the
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ERBB2/Her2-neu amplified patients, 50% (n = 12) of
them found to carry mutation in the genes we studied,
whereas remaining patients (n = 12) did not harbour mutation in the genes. However no significant survival differences were observed between amplified and non-amplified
group. In addition, when fold change in expression between tumour and normal group were compared, no significant difference was observed (Wilcoxon signed rank
test, p = 0.91). We have checked ERBB2/Her2-neu expression in few of the ERBB2/Her2-neu amplified tumour
samples and observed overexpression in the tumour tissues compared to adjacent normal tissues, so amplification
data followed the expression data (data not shown). Ideally
the ERBB2/Her2-neu amplification results need to be validated by other methods like, in situ hybridization and immunohistochemistry (IHC), but it is limited by relevant
tissue availability in our study.

Discussion
Present study highlights mutational landscape of PAC and
PDAC in Indian patients. In our targeted NGS discovery
effort on 8 (PDAC and PAC tumours) and subsequent validation in another additional 85 more tumour tissues, we
identified frequent mutations in genes like TP53, KRAS,
SMAD4, CTNNB1, and ERBB3. Though, we have performed 8 paired (PDAC and PAC) samples, for targeted
NGS studies, but after 10,000 times simulation with randomly taken 8 samples from databases showed similar sets
of genes mutated in the diseased samples. This result confers the same genetic model predisposed if we increased
the sample sizes in our discovery sample set. In multiple
cancer types, all of these above 5 genes have been reported
as driver genes with an array of frequently reported
hotspot pathogenic mutations (Bailey et al. 2018). The
KMT2C gene harbouring 5 somatic mutations in 3 of the
8 discovery tumours is one of the most frequently mutated
genes among chromatin remodelling factors (GonzalezPerez et al. 2013) identified in PDAC tumours, but all
detected mutations loci are spread over 56 exons of the
gene, making the validation experiment design significantly harder to pursue.
Adenocarcinomas are known to exhibit relatively
lower frequency of G:C > T:A transversion than G:C > A:
T transition in PDAC and periampullary adenocarcinoma. Lower percentage of G:C > T:A transversion and
higher percentage of G:C > A:T transition are consistent
with our findings in pancreatic ductal and periampullary
adenocarcinomas. Laboratory studies showed that the
most common mutation caused by an alkylating agent is
G:C > A:T transition (Greenblatt et al. 1994). Previously,
it was reported substitution was 38% at CpG dinucleotides and 15% at TpC dinucleotides in PDAC cases
(Jones et al. 2008). In our cases, only 13% of the
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Fig. 6 Tissue microarray analysis of Tp53 IHC staining. Staining is scored as follows; a & b TP53 p.A138V mutant tumours, c TP53 p.R175H mutant
tumour, d TP53 p.E285K mutant tumour. All these above sections represents overexpression (OE) showing nuclear staining with strong intensity in
> 70% tumour cell nuclei. e Tp53 null positive control tumour showing complete absence (CA) of expression in tumour cells. f Tp53 wild type
tumour section showing nuclear staining with variable intensity in 1–80% of tumour cell nuclei or < 10% of tumour nuclei with strong intensity.
All these section represents tissue microarray of pancreatic ductal and periampullary adenocarcinoma. All the above immunohistochemical
snapshot was captured at 100 um from the respective TMA images

substitutions were at CpG dinucleotides and 22% of the
mutations were identified in TpC dinucleotides.
In our discovery cohort, frequency of KRAS mutations
were 12% (S-Fig. 14), the result was consistent with our
validation cohort (21%). KRAS however is more common
(33%) among the PDAC patients. Interestingly, KRAS
12th codon mutation screening in another 24 PDAC independent cohort showed 33% mutations, which
was consistent with our findings from previous patient
cohort. In contrast, it was also known from earlier studies that KRAS was mutated in almost 70–90% of PDAC
patients (Waters and Der 2018). Recent report from the
TCGA datasets of 149 PDAC patients, showed mutation
frequencies of major drivers KRAS, TP53, SMAD4, and
CDKN2A are 93, 72, 32, and 30% respectively (Cancer
Genome Atlas Research Network 2017). Disease progression model of PDAC confirmed that KRAS mutations are one of the earliest genetic events in normal
duct to malignant transformation (Witkiewicz et al.
2015; Hruban et al. 2000; Eser et al. 2014). Ampullary
tumours too harbour high frequency of KRAS mutations
(40–50%) (Jones et al. 2008; Mikhitarian et al. 2014). In
both PDAC and PAC, more than 90% of KRAS mutation
occurs in 12thcodon (Prior et al. 2012; Bryant et al.
2014). So, in addition to Sanger sequencing and ASPCR
approaches, we performed an RFLP based KRAS 12th
codon mutation detection assay in another 24 PDAC

tumours as well as in the validation cohort. Among the
24 PDAC tumours, 8 (33%) found to harbour this
KRAS 12th codon mutation, suggesting a congruence
with the validation cohort results. Similar to previous reports, this study also identified almost 80% of all the
KRAS mutation at 12thcodon among all KRAS mutations
in our PDAC tumours. Most of the European studies observed 72–83% of KRAS mutation whereas Korean studies observed only 47–52% KRAS mutation in PDAC.
However, Japanese and Chinese pancreatic patients
showed 94 and 71% KRAS mutation prevalence respectively (Song et al. 2000; Kwon et al. 2015). In pancreatobiliary malignancies the KRAS point mutation frequency
known to vary between 75 and 100%, however OliveiraCunha et al. (2012), observed only 41% PAC patients
had KRAS mutation in their primary tumours (OliveiraCunha et al. 2012). We observed a similar trend like
colorectal cancer (CRC), in which an Indian cohort detected to have only 20.5% KRAS mutated patients, compared to~ 40% KRAS mutants in Western counterparts
(Patil et al. 2013). Even in non small cell lung cancer
(NSCLC), frequency of KRAS mutations differs between
Caucasians and East Asian populations (25–50% and 5–
15% respectively) (Choughule et al. 2014). A very recent
cfDNA analysis revealed that KRAS mutation frequencies vary from 39 to 47% in PDAC patients from different studies (Gall et al. 2019). Till date, only one study
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Fig. 7 Survival analysis of combinational of polymorphisms in TP53, MDM2 and P73 genes. Overall survival comparison between patient’s group
and combination of SNP markers of TP53, and its associated genes. In both picture (a & b) “1” indicates to patients containing risk genotypes and
“0” indicates to patients containing non risk genotypes of all three loci. a. Kaplan-Meier OS analysis of patients with risk allele containing
genotypes in TP53 codon 72 (R/R, or R/P), MDM2 SNP 309 (G/G, or T/G) and P73 73 bp deletion (D/D, or I/D) loci that denoted as () vs at least two
loci with non risk genotype b. Kaplan-Meier OS analysis of patients with I/I genotypes (non risk) of P73 (73 bp Indel) polymorphism in
combination with risk genotypes of TP53 codon 72 (R/R, or R/P), and MDM2 SNP 309 (G/G, or T/G) loci vs all of the patients carrying at least two
loci with non risk genotypes. Number of patients with respective genotypes denoted by “n” in each of the survival curves

from India reported 31% of PDAC patients harboured
KRAS mutations using cfDNA based assay (Singh et al.
2015). Our data also supported the previous finding on
Indian patients that KRAS mutation frequency varied
from 30 to 33% in Indian PDAC cohort. Based on all
previous observations on pancreatic, colorectal and
NSCLC tumours in different world-wide population
samples, we interpret that KRAS somatic mutations frequency is very much a population specific phenomenon
which definitely is reminiscent of the fact that “one size
fits all” population idea may not be valid here too. It is
not very well understood why PDAC is associated exclusively with KRAS mutations in contrast to our observation. One explanation for the isoform specificity of RAS

driven tumour formation could be explained by the fact
that certain tissues are exposed to different carcinogens
and environmental insults that result in mutations is
specific to RAS genes. In addition to tissue based isoform specificity the frequency of different KRAS missense mutations can vary in different cancer types
(Waters and Der 2018).
Erb-B2 receptor tyrosine kinase 2 (ERBB2/Her2-neu) is
a member of the ErbB-RTK family which comprises four
closely related RTKs, such as EGFR, ErbB2, ErbB3 and
ErbB4. ErbB2 dimerizes with itself or other ErbB members to activate downstream signalling pathway, such as
PI3K-AKT. ERBB2/Her2-neu gene amplification occurs
in a wide variety of human cancers (Ying et al. 2016). In
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our study, almost 19% of the PDAC patients showed
ERBB2/Her2-neu amplification, whereas 30% of the PAC
patients showed ERBB2/Her2-neu amplification in the
tumour. Focal amplification of receptor tyrosine kinases
(RTKs) such as ERBB2, EGFR, MET, and FGFR1 have
been already reported in PDAC (Assenat et al. 2015).
Previously, ERBB2 amplification also reported in ampullary adenocarcinoma ranging from 13 to 15% (Hechtman
et al. 2015). The ERBB2/Her2-neu -targeted therapies,
such as trastuzumab, lapatinib and pertuzumab, have
showed improved outcomes in patients with ERBB2/
Her2-neu amplification-positive cancers, and these drugs
have been approved by the FDA against ERBB2/Her2neu-positive gastric and breast cancers (Ying et al. 2016).
In our study among the ERBB2/Her2-neu amplified
group, 50% patients showed no mutation in any of the
other most frequently mutated driver genes, indicating it
can be a target of high therapeutic impact potential in
ERBB2/Her2-neu positive PDAC and PACs.
The WNT signalling pathway has been previously reported to be implicated in PAC. Our study identified 7%
mutations in CTNNB1, frequently at the 45th codon.
Three of the mutations were identified in PDAC and
remaining 3 mutations were identified in PAC cases. In
case of PDAC, several studies (Bailey et al. 2016; Witkiewicz et al. 2015) reported mutations in WNT signalling
pathway but not frequently in CTNNB1 gene. On the
other hand, in the case of periampullary tumours WNT
signalling pathway was most frequently mutated in intestinal type than pancreatobiliary subtype (67% vs. 30%)
(Gingras et al. 2016). Mutations in CTNNB1 along with
APC, SOX9 and FBXW7 were reported to be most frequent among periampullary tumours (Gingras et al.
2016). The increased rate of CTNNB1 mutations and
WNT alterations could greatly impact the choice of
treatment since several WNT pathway targeted therapies
are in the process of development.
In a previously published paper, the TP53,tumour suppressor gene (TSG) was reported to be inactivated in
40–75% of pancreatic tumours and among all cancers,
75–90% of somatic mutations were observed in the DBD
of TP53 (Hainaut and Pfeifer 2016). In our patient cohorts, TP53 mutations were observed in 41% of the patients. Majority of the patients carrying TP53 mutations
were diagnosed in between stages IIA-IIB suggesting
early inactivation of TP53 during malignant transformation as in lung, head & neck and breast tumours. Interestingly, 3% of the patients showed more than one nonsynonymous mutations in TP53. This finding suggests
parallel evolution theory of tumour cells, where distinct
lineages acquire mutations in the same cancer driver
gene, leading to parallel subclonal expansion (Lawrence
et al. 2013). The various kinds of TP53 DBD mutations
were identified in our patient cohort. Strikingly, p.A138V
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(17%) was the most frequent mutation among them (Fig.
3a). The Majority of p.A138V mutated cases were observed in PDAC (25%) but less in PAC (12%). In TCGA
database, the frequency of p.A138V mutation in mTP53
is 0.04% but no report in PDAC, though, this region is
well conserved in different species.
Interestingly, it was found from the previous literature
that p.A138V mutation in TP53 was reported as both
germline and somatic alteration in few studies (Lee et al.
2012). Similar to their observations we also detected
p.A138V TP53 as germline mutation in two of the patients (2%) (data not shown). However, we also screened
this mutation in 130 unrelated healthy individuals collected from same population but none of them was
found to carry this p.A138V mutation (data not shown).
In-silico analysis with Align-GVDV predicted it to be
likely deleterious (Petitjean et al. 2007). Earlier in-vitro
studies suggested p.A138V is a temperature sensitive
mutant (Milner and Medcalf 1990; Christgen et al.
2012). Recently, an in-silico study identified driver genes
and mutations in cancers, by mutation clustering in
three dimensional (3D) protein structures using mutations in 11,119 tumour samples across 41 tumour types
with dataset contained 11,82,802 somatic missense mutations occurring in 10,25,590 residues in 18,100 genes.
The p53 identified as the largest number of residues in
3D clusters. In 3038 rarely mutated residues in p53 that
were clustered in 3D, p.A138V/P/T identified as one of
the significant hotspot (p = 0.02) (http://www.3dhotspots.org) (Gao et al. 2017). In a recent high throughput
functional screening study for all possible DNA binding
mutations in TP53, p.A138V hotspot mutation at TP53
was found to have similar functional score (RFS > 0) as
the well known TP53 cancer hotspot positions (p.R175H,
p.G245S, p.R248Q, p.R249S, p.R273H and p.R282W)
(Kotler et al. 2018). A molecular docking simulation
(MDS) study reported that A138 codon of p53 is located
at the interface of chain A and B of p53 dimer and DNA
complex. The residue is conserved as well as surface exposed and considered as one of the binding hotspot
amino acid loci (Ma et al. 2005). In addition to that, our
MDS analysis (RMSF, SSE and Trajectory clustering)
showed higher lability in the p.A138V mutant DBD compared to that of DBD of wild type p53. The predicted
binding energy (as measured by docking score) suggests
greater stability for wild type DBD of p53 compared to
mutant one (S-Tab. 7). Overall, the mutant protein form
is predicted to have a higher plasticity and higher degree
of flexibility. All of these simulation derived characteristics showed consistent similarities with other well characterized hotspot drivers at TP53 loci (p.R175H, p.Y220C,
p.G245S, p.R248Q, p.R249S, p.R273H, and p.R282W)
(Demir et al. 2011; Lepre et al. 2017). In addition, MDS
also exhibited that p.A138V hotspot TP53 mutant might
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have structural destabilization, and lesser affinity towards
DNA molecule compared to the native form. Previous
study reported similar results with p.R273H cancer hotspot mutation in p53 protein, losing its stability and becoming more rigid (Kamaraj and Bogaerts 2015).
Subsequently, we performed a protein DNA docking analysis and intermolecular hydrogen bonding pattern simulation. As per this analysis, we have predicted p.A138V
mutant form would have a significant affinity loss with
DNA.
We also performed immunostaining of p53 p.A138V
mutant cancer cases along with some other missense
mutants. The majority of the TP53 mutations are predominantly clustered in the DNA binding domain. Most
of the mutations were associated with strong or intermediate staining of p53. In the MD simulation and
docking study, we predicted that p.A138V has oncogenic
properties like other known TP53 hotspot mutants. Tissue Micro Array staining results also demonstrated that
p.A138V has salient features like strong nuclear retention/stabilization in the nuclei, which is commonly observed in TP53 hotspot/GOF mutants in cancer (Guedes
et al. 2017). Additionally, survival analysis derived results
showed this mutation associated with poor prognosis of
the patients (p = 0.01). Previously, multitude of retrospective studies have associated abnormal p53 protein
expression as well as somatic mutation with poor survival or lack of response to therapy. For cancers of the
breast, head and neck, liver, hematopoietic, and lymphoid systems, a majority of studies showed an association
of TP53 mutations with poorer survival. However for
cancers of the bladder, brain, lung, colon, esophagus,
and ovary, several studies found no association of OS
with TP53 mutations (Robles and Harris 2010). In our
study we found p.A138V mutated TP53 was associated
with poor OS of the patients. Furthermore, we also compared patient survival difference of p.A138V mTP53 patients with other TP53 hotspot mutants (such as
p.R175H, p.R248W, p.R248Q, and p.R282W) of TCGA
PDAC cohort data but no significant difference was observed among them (S- Fig. 15). All these evidences
from previous observations and our findings concluded
that p.A138V somatic alteration at TP53 might have
oncogenic role in development of PDAC and PAC in
our patient population. We observed a very little overlap
of KRAS and TP53 pathogenic mutations in PDAC and
PAC in these patients. It might be suggesting a possibility that a major fraction of PDAC and PAC carcinogenesis might have been facilitated by TP53 mediated
signalling pathways in a KRAS mutation independent
manner. Rowley et al. (2011) demonstrated that inactivated BRCA2 inhibited KrasG12D associated pancreatic
tumour but acted synergistically with disrupted TP53 to
promote pancreatic cancer in mice (Rowley et al. 2011).
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Similarly, detection of KRAS independent high frequency
recurrent TP53 mutation suggests the possibility of a
newer pancreatic or pancreatobiliary carcinogenic transformation model for Indian patients. This could be due
to differential lifestyle exposure and genetic composition
making the studied Indian patients somewhat unique
from their western counterparts. The OS analysis
showed patients with pancreatic tumour surviving worse
compared to patients with periampullary tumour. The
previous reports also suggests the 5 year survival rate in
PDAC is 6–8% whereas 30–50% in PAC patients (Chandrasegaram et al. 2016). Altogether, 50% of the all identified variants in our study found to be reported in TCGA
database. But when we matched the mutation data of
our PDAC patient cohort with mutation data of TCGA
PDAC patient cohort, only 13% of the missense and
nonsense mutations corroborated.
Different tumour types show different spectra of TP53
mutations. The frequency of missense mutations also
differs in different subclasses of tumours of the same
organ. Our data indicated that TP53 p.A138V mutation
is more frequent in PDAC and pancreatobiliary type of
PAC. Above identified mutation is very uncommon in
patients from other parts of the world. The new attractive therapeutic avenues point towards reactivation of
some level of wild type function in mutant p53. A variety
of compounds were recently identified, that might restore wild type p53 function. In addition to that, Short
Interfering Mutant p53 Peptides (SIMPs) specific to the
mutant p53 protein can restore the wildtype activity
(Blandino and Di Agostino 2018; Muller and Vousden
2014). The identified hotspot mutation p.A138V could
also be used as a therapeutic target like several other
TP53 hotspot mutations. Downstream pathways of TP53
p.A138V mutant may also be crucial for therapeutic
intervention targets. Additionally, in the present study
we observed TP53 p.A138V mutated patients have
poorer survival suggesting this could be an useful prognostic biomarker. However, our data did not suggest any
significant association between KRAS mutations and patient’s survival (data not shown). In contrast, other studies found significant association between KRAS mutation
and poor prognosis (Kwon et al. 2015). TP53 tumour
mutations can be induced by environmental exposures
that are distinctly different from patterns in other kind
of cancers. This is what one might anticipate when different cancer types are associated with different risk factors that cause different mutation patterns in
experimental systems. The codon 249 at TP53 is highly
mutated in hepato cellular carcinoma (HCC), due to exposures of aflatoxin B1, whereas in lung cancers, TP53
mutations cluster at several codons, 157, 245, 248, and
273 due to exposures of tobacco smoke carcinogen metabolite, benzo-(a) pyrenediol-epoxide (BPDE). In
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melanoma, certain TP53 mutations occur via exposures of
sunlight (ultra-violet light) (Hollstein et al. 1998). The p53
protein has Cys3His1-typed zinc finger domain. Chronic
toxicity from persistent exposure of heavy metal ions are
weak mutagens in mammalian cells and has effects on zinc
finger domain of p53 protein structure. Thus, impairment of
p53-DNA binding capacity and inhibition of cell cycle arrest
occurs (Koedrith and Seo 2011). With all previous facts explained by different group of researchers, we hypothesized
that in case of our studied tumours, there might be specific
exogenous carcinogens that have been conclusively linked
with development of cancers. In our studied patient population, tobacco smoking habits and alcohol drinking habits
were comparatively low (S-Tab. 3). However, most of the
patients come from villages of West Bengal (one of the eastern states of India) and belong to low socioeconomic status
group who may have had exposures of heavy metal particles
through water intake, several kinds of occupational exposures and chemical exposures in agricultural field. Previously
it was also reported that pancreatic cancers are associated
with pesticide exposures, industrial chemicals, chlorinated
hydrocarbons, solvents and nickel, organochlorines, and
chromium (Andreotti and Silverman 2012).
There is a large body of evidence that suggest that p53
stress response pathway harbours inherited polymorphisms
that affect p53 signalling in cells, resulting in differences in
cancer risk and clinical outcome in humans. Previous studies
inferred inherited variations in P53 pathway components
may define patient populations in their abilities to produce
apoptosis of cancer cells in response to DNA damage induced by chemotherapeutic agents (Grochola et al. 2010).
While studying joint effect of SNPs of TP53 and its associated genes, with patient survival, we found TP53 R72P polymorphism in combination with MDM2 T309G and p73
InDel 73 bp polymorphism played substantial roles in poor
prognosis of PDAC and PAC. This suggests that the combined effect of ‘R’ allele in TP53 codon 72, ‘G’ allele of
MDM2 SNP 309 and “D” of p73 Indel 73 bp has adverse effect among all PDAC and PAC patients regardless of somatic
TP53 mutation. We took a closer look at TP53 as we genotyped 3 well known cancer associated polymorphisms
(R72P-rs1042522, PIN3 InDel 16bp, Intron 6 MspIrs1625895) in TP53. Haplotype analysis of these polymorphisms showed no significant differences in haplotypes frequency estimation between TP53 mutant and non mutant
group (S-Tab. 9). Additionally, we also investigated whether
individual polymorphism or in combination of polymorphisms in TP53 (R72P-rs1042522, PIN3 InDel 16 bp, Intron
6 MspI- rs1625895), p73 InDel (73 bp deletion), p21 (codon
31- rs1801270), and MDM2 (SNP 309- rs2279744), associated with mutant group. However, in both logistic regression
and MDR model test showed no significant association, between risk SNP or in combination of risk SNPs with TP53
somatic mutated patient group (S-Tab. 10 and 11). We could
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not correlate this specific combination of risk SNPs with
somatically DBD mutated TP53 patients (data not shown).
To our knowledge, this novel finding is reported for the first
time in PDAC and PAC disease groups. Similar to our result
Liu et.al (2011) also showed the collective effect of TP53,
MDM2, and p73 risk polymorphisms that have significant
impact on prognosis of NSCLC patients (Liu et al. 2011).
Some limitations must be considered to interpret the
data of our study. At first, we studied only selected cancer related genes so did not observe any alteration in
these genes in 31 patients (33%), suggesting that different driver genes were involved in those patients. Those
could have been better studied by whole exome/genome
studies. Second, the sample size in the targeted study for
NGS was only 8, which may have led to identification of
less number of frequently mutated genes. Third, although we checked the tumour purity (> 70%) for almost
all samples, we might have missed low frequency mutations (< 20%) (Rohlin et al. 2009) in samples as Sanger
sequencing may not have identified such low frequency
mutations. Fourth, the sample size for polymorphism
and somatic mutation association study needed more
samples for better result. Lastly, no satisfactory explanation could be given for low KRAS mutation frequency
in Indian PDAC patients without studying a much larger
cohort. It would be ideal in the future to validate the Indian PDAC patients’ KRAS mutation frequency in a statistically valid large Indian cohort.

Conclusions
We, for the first time, revealed the mutational spectrum of
some frequently mutated genes in PDAC and PAC patient
cohort from India. We observed high frequency of a rare
variant, p.A138V at TP53 which could be considered as a
novel hotspot cancer mutation. This may have oncogenic
property as indicated by our experimental results (MDS
and TMA studies) as well as a previous functional screening study. Our study identified TP53 driven mechanism to
be a dominant player over KRAS signalling networks,
pointing to different environmental exposures in disparate
geographical locations of Indian and Western countries.
We identified a very low frequency of KRAS mutations
compared to patients from Western countries and confirmed the data with 4 different experimental methods.
This indicates the mutational landscape of frequently mutated genes in PDAC and PAC differs in our patient population with previous studies. In future, p.A138V hotspot
oncogenic mutation may help clinicians for further patient
stratification and therapeutic management to improve
outcomes for this morbid diseases. To our knowledge, this
is among the first studies to demonstrate that a specific
TP53 mutation is associated with poor prognosis of
pancreatic cancer such as PDAC and PAC.
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Additional file 1: Fig. 1. Hematoxilin and Eosin (H&E) staining of types
of tumors. a. H&E staining of a PDAC tumor (left 10x magnification, right
20x magnification). b. H&E staining of an intestinal type of PAC tumor
(left 10x magnification, right 20x magnification). c. H&E staining of a
pancreatobiliary type of PAC tumor (left 10x magnification, right 20x
magnification). Fig. 2. Validation of selected variants. Few of the somatic
mutations identified in NGS study are being validated by Sanger
sequencing method. Validated nucleotides are marked by vertical lines, in
each pair upper one is for tumor DNA and lower one is for normal tissue
or blood DNA. Fig. 3. Signature of somatic mutations identified in total
patient cohort (n = 93). a. In the X axis different types of mutations is
given and Y axis denoting frequency of types of mutations. b. Transition
and transversion ration of all point mutations. c. In X axis six different
signatures of point mutations is given and Y axis denoting the frequency
of different signatures. Fig. 4. Frequency of mutations in other
recurrently mutated genes in all patients. Different functional domains of
proteins are indicated by different colours. The Y axis denotes frequency
of mutations and X axis denotes mutations in different positions of the
protein domains. Each vertical bar indicates mutation . Recurrent
mutations are marked with red circle a. KRAS mutations.b. SMAD4
mutations. c. CTNNB1 mutations. Fig. 5. Damaging and pathogenic
variants of non synonymous mutations (n = 57). Damaging and
pathogenic variants of non synonymous mutations (n = 57). The dark ass
coloured boxes indicates mutations identified as damaging by different
functional prediction tools (Provean, SIFT, and Mutation Assessor). The
white coloured boxes mean the tolerated mutations whereas light grey
coloured boxes mean “unable to identify”. All the dark grey coloured
boxes in the ClinVar_Status row indicate pathogenic or likely pathogenic
variants and black coloured boxes are reported as uncertain significance
in ClinVar database. Fig. 6. Comparison of reported and novel variants
observed in this study with those reported in TCGA and Cosmic
database. These are the total mutations identified by both NGS and
Sanger sequencing method. The blue coloured boxes in sample row are
PAC mixed samples, Sky coloured boxes are PAC intestinal samples, Grey
coloured boxes are PAC pancreatobiliary samples and yellow coloured
boxes are PDAC samples. The red colouredboxes in COSMIC and TCGA
row are the reported mutation in these databases. The boxes marked
with “×” in TCGA_PDAC row are not compared as these are PAC
mutations data. Among the PDAC samples, red coloured boxes are the
mutations which were also observed in TCGA_PDAC (n = 185) mutation
data. Fig. 7. Detection of KRAS and TP53 p.A138V mutations by allele
specific PCR (a-f). Fig. 8. KRAS 12th codon mutation detection by PCRRFLP method. Lane 1 represent 100 bp DNA ladder. Lane 2 to 11 represents tumour normal paired samples. Mutant samples can be differentiate
with presence of 197 fragments in T1, T2, T3, and T5 as BstNI cannot digest mutant containing fragment. Here sample T4-N4 pair is negative
control and T5-N5 pair is positive control of NGS cohort. Fig. 9. KRAS mutation screening by different methods in PDAC samples. First row indicates KRAS mutation status in 36 PDAC samples. The yellow colour
indicates G12D mutations, violate colour indicates G12V mutation, sky
colour indicates Q61H mutation, green colour indicates G12A mutation,
no colour boxes indicate samples with no mutation, and light grey colour
indicates samples with failed amplification or poor sequence quality.
Other rows indicate different methods (Sanger sequencing, ASPCR, and
PCR-RFLP) used for KRAS mutation detection. In the methods rows, red
colour indicates identification of mutation, white colour indicates mutations could not be identified, and dark ash colour indicates not applicable
due to PCR failure for those samples. Fig. 10. Identification of p.A138V
mutation in TP53 gene by Sanger sequencing. The p.A138V mutation in
TP53 identified in 16 patients. Here showing two chromatogram (a&b) for
p.A138V (Vertical line indicates C/T heterozygous peak) variant identified
by Sanger sequencing in 2 patients in the tumour but absent in corresponding normal. Fig. 11. Comparison SSE plots between wild type
TP53and A138Vmut TP53. Fig. 12. Intermolecular hydrogen bonding analysis between TP53 (DBD) and DNA complex with respect to wild type
and A138Vmut TP53 protein. Number of intermolecular hydrogen bonds
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between TP53(DBD) (wild type and mutant) and DNA represented in a
multivariate plot which shows greater density of data points at 8–12 in
wild type (left) and in 5–10 for the mutant (right). Therefore, greater number of intermolecular hydrogen bonds prevailed in the wild type DBDDNA dynamics simulation than in the corresponding mutant DBD-DNA.
Fig. 13. Copy number variation plot for ERBB2 in 93 patients. “X” axis denotes two groups of tissues (Normal and Tumour) of all patients whereas
“Y” axis indicates fold change (2-ΔCT) of respective groups. Fig. 14. KRAS
hotspot region of 8 tumor samples studied by NGS. Showing reads of
KRAS gene focusing on hotspot codon 12 of 8 samples (a-h). Integrative
Genomic Browser (IGV) was used for visualization of reads. In figures,“a-h”
except “e”, only “C” allele is present in the particular position of KRAS
gene, whereas figure“e” indicated “C” and mutant “G” alleles in same position. In figure e the variant allele “G” is represented by orange coloured
on the reads. Fig. 15. Comparison of overall survival of p.A138V mutant
vs. other TP53 hotspot mutants of TCGA PDAC cohort. Kaplan-Meier survival analysis of all TP53 hotspot mutants of TCGA PDAC cohortalong
with TP53 A138V mutants of our patient.
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